- Price
- $1,152.22
- Day
- -0.02%
- Mkt Cap
- $1.09T
- 52W Range
- $712.05 – $1,292.65
- Volume
- 4.48M
- Beta
- 0.50
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 500 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum and is suitable for investors in the accumulation phase.
Read full article
Eli Lilly has generated explosive growth thanks to its weight loss drug portfolio. Costco's focus on bargain prices keeps customers loyal -- and membership renewal rates surpass 90%.
Read full article
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.
Read full article
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone, among patients with ESR1-mutated MBC The all-oral combination of Inluriyo and Verzenio gives patients a treatment approach that targets the two central drivers of ER+ breast cancer, with an established tolerability profile and no new monitoring required INDIANAPOLIS, Sept. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Read full article
The US FDA has approved Eli Lilly's drug combination to treat adults with a type of advanced breast cancer that has spread to other parts of the body, the drugmaker said on Friday.
Read full article
Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. Lilly and rival Novo Nordisk launched weight loss pills this year, and so far, Novo is leading in prescriptions.
Read full article
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read full article
It's impossible to take all the risk out of investing. But that doesn't mean investors can't make a good attempt.
Read full article
There is a correlation between increasing dividends and strong investment performance — even if a stock has a low dividend yield when you buy.
Read full article
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
Read full article